{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:52:00Z","timestamp":1793256720385,"version":"4.5.0"},"reference-count":110,"publisher":"American Medical Association (AMA)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,11,19]]},"abstract":"<jats:sec id=\"ab-jrv240029-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>\n                      A global outbreak of clade IIb\n                      <jats:italic>Monkeypox virus<\/jats:italic>\n                      (MPXV) infections spread rapidly across at least 118 countries resulting in a Public Health Emergency of International Concern (PHEIC) from July 2022 to May 2023. This outbreak affected more than 99\u202f000 persons worldwide and caused more than 33\u202f000 infections and 60 deaths in the US. In 2024, there have been approximately 200 new infections per month in the US. On August 14, 2024, the World Health Organization declared mpox a PHEIC for a second time due to a rapid increase in infections with clade I MPXV in Central Africa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240029-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Mpox is primarily acquired through direct skin to skin contact with MPXV. With clade IIb MPXV, infections are most commonly associated with sexual activity among individuals who are gay, bisexual, and other men who have sex with men. After a median incubation period of 7 to 10 days, prodromal symptoms include fever (62%-72%), lymphadenopathy (56%-86%), myalgias (31%-55%), malaise (23%-57%), and headache (25%-55%). Skin lesions progress through 4 well-defined stages (macules, papules, vesicles, and pustules) over 2 to 4 weeks. Clade IIb MPXV is typically a self-limited illness with a low mortality rate (&amp;amp;lt;0.2% in the US); however, severe illness and death may occur in immunocompromised individuals, especially those with advanced HIV (CD4 count\u2009&amp;amp;lt;200 cells\/\u03bcL). Mpox should be suspected in patients with potential exposure to MPXV who have skin lesions, and the diagnosis is confirmed with polymerase chain reaction testing of lesions. Management is supportive and focuses on skin care and symptom relief with analgesics. While no antiviral treatments are currently approved for mpox by the US Food and Drug Administration, several therapeutics, such as tecovirimat, brincidofovir, and vaccinia immune globulin intravenous, are available through expanded access programs or clinical trials. Vaccination with the 2-dose Modified Vaccinia Ankara-Bavarian Nordic vaccine is recommended for high-incidence populations and has an efficacy of 66% to 86%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240029-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Mpox is a viral infection transmitted primarily through close skin to skin contact that typically causes a self-resolving illness but can result in severe illness and death in immunocompromised individuals. First-line therapy is supportive care, although patients with severe mpox infection may be treated with advanced therapeutics. Mpox vaccination is effective and, if available, should be offered to individuals at risk of exposure to mpox.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2024.21091","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T13:30:28Z","timestamp":1728912628000},"page":"1652","source":"Crossref","is-referenced-by-count":183,"title":["Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies"],"prefix":"10.1001","volume":"332","author":[{"given":"Boghuma K.","family":"Titanji","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniruddha","family":"Hazra","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, Illinois"},{"name":"Howard Brown Health, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Zucker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"jrv240029r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2022.198932","article-title":"The virology of human monkeypox virus (hMPXV): a brief overview.","volume":"322","author":"Lansiaux","year":"2022","journal-title":"Virus Res"},{"issue":"45","key":"jrv240029r3","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.15585\/mmwr.mm7145a4","article-title":"Epidemiologic features of the monkeypox outbreak and the public health response\u2014United States, May 17-October 6, 2022.","volume":"71","author":"Kava","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"36","key":"jrv240029r4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.15585\/mmwr.mm7136a1","article-title":"HIV and sexually transmitted infections among persons with monkeypox\u2014eight US jurisdictions, May 17-July 22, 2022.","volume":"71","author":"Curran","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"jrv240029r6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.15585\/mmwr.mm7220a2","article-title":"The CDC domestic mpox response\u2014United States, 2022-2023.","volume":"72","author":"McQuiston","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"jrv240029r7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/v15030727","article-title":"Identifying the most probable mammal reservoir hosts for monkeypox virus based on ecological niche comparisons.","volume":"15","author":"Curaudeau","year":"2023","journal-title":"Viruses"},{"issue":"2","key":"jrv240029r8","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28534","article-title":"Transmission of monkeypox\/mpox virus: a narrative review of environmental, viral, host, and population factors in relation to the 2022 international outbreak.","volume":"95","author":"Pan","year":"2023","journal-title":"J Med Virol"},{"issue":"4","key":"jrv240029r9","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1016\/S2666-5247(23)00034-4","article-title":"Mpox respiratory transmission: the state of the evidence.","volume":"4","author":"Beeson","year":"2023","journal-title":"Lancet Microbe"},{"issue":"35","key":"jrv240029r10","doi-asserted-by":"publisher","first-page":"758","DOI":"10.15585\/mmwr.mm7335a1","article-title":"Contact tracing for mpox clade II cases associated with air travel\u2014United States, July 2021-August 2022.","volume":"73","author":"Delea","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"jrv240029r11","doi-asserted-by":"publisher","first-page":"e288","DOI":"10.1016\/S2666-5247(23)00059-9","article-title":"Airborne transmission of MPXV and its aerosol dynamics under different viral load conditions.","volume":"4","author":"Lee","year":"2023","journal-title":"Lancet Microbe"},{"issue":"11","key":"jrv240029r12","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1038\/s41591-022-02004-w","article-title":"Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium.","volume":"28","author":"De Baetselier","year":"2022","journal-title":"Nat Med"},{"issue":"3","key":"jrv240029r13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/infdis\/jiad091","article-title":"Time scales of human mpox transmission in the Netherlands.","volume":"229","author":"Miura","year":"2024","journal-title":"J Infect Dis"},{"issue":"5","key":"jrv240029r14","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28769","article-title":"Presymptomatic viral shedding in high-risk mpox contacts: a prospective cohort study.","volume":"95","author":"Brosius","year":"2023","journal-title":"J Med Virol"},{"issue":"10","key":"jrv240029r15","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41577-022-00775-4","article-title":"Monkeypox: disease epidemiology, host immunity and clinical interventions.","volume":"22","author":"Lum","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"jrv240029r16","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.antiviral.2018.11.004","article-title":"Vaccinating against monkeypox in the Democratic Republic of the Congo.","volume":"162","author":"Petersen","year":"2019","journal-title":"Antiviral Res"},{"issue":"4","key":"jrv240029r17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/QCO.0000000000000933","article-title":"Mpox exposure and transmission in healthcare settings during the 2022 global outbreak.","volume":"36","author":"Zachary","year":"2023","journal-title":"Curr Opin Infect Dis"},{"issue":"38","key":"jrv240029r18","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.15585\/mmwr.mm7138e2","article-title":"Health care personnel exposures to subsequently laboratory-confirmed monkeypox patients\u2014Colorado, 2022.","volume":"71","author":"Marshall","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"19","key":"jrv240029r21","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMra2208860","article-title":"Monkeypox.","volume":"387","author":"Gessain","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv240029r22","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac310","article-title":"Monkeypox: a contemporary review for healthcare professionals.","volume":"9","author":"Titanji","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"10370","key":"jrv240029r23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0140-6736(22)02075-X","article-title":"Monkeypox.","volume":"401","author":"Mitj\u00e0","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"jrv240029r24","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1086\/498115","article-title":"Clinical characteristics of human monkeypox, and risk factors for severe disease.","volume":"41","author":"Huhn","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"23","key":"jrv240029r25","doi-asserted-by":"publisher","first-page":"764","DOI":"10.15585\/mmwr.mm7123e1","article-title":"Monkeypox outbreak\u2014nine states, May 2022.","volume":"71","author":"Minhaj","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"24","key":"jrv240029r26","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200448","article-title":"Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022.","volume":"27","author":"Miura","year":"2022","journal-title":"Euro Surveill"},{"issue":"10353","key":"jrv240029r27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(22)01436-2","article-title":"Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study.","volume":"400","author":"Tar\u00edn-Vicente","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"jrv240029r28","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMoa2207323","article-title":"Monkeypox virus infection in humans across 16 countries\u2014April-June 2022.","volume":"387","author":"Thornhill","year":"2022","journal-title":"N Engl J Med"},{"issue":"32","key":"jrv240029r29","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.15585\/mmwr.mm7132e3","article-title":"Epidemiologic and clinical characteristics of monkeypox cases\u2014United States, May 17-July 22, 2022.","volume":"71","author":"Philpott","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"jrv240029r30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072410","article-title":"Clinical features and novel presentations of human monkeypox in a central London centre during the 2022 outbreak: descriptive case series.","volume":"378","author":"Patel","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"jrv240029r31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/infdis\/156.2.293","article-title":"Human monkeypox: clinical features of 282 patients.","volume":"156","author":"Je\u017eek","year":"1987","journal-title":"J Infect Dis"},{"issue":"2","key":"jrv240029r32","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/cid\/cit703","article-title":"Human monkeypox.","volume":"58","author":"McCollum","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"4","key":"jrv240029r33","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.idc.2019.03.001","article-title":"Human monkeypox: epidemiologic and clinical characteristics, diagnosis, and prevention.","volume":"33","author":"Petersen","year":"2019","journal-title":"Infect Dis Clin North Am"},{"issue":"10367","key":"jrv240029r34","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1016\/S0140-6736(22)02187-0","article-title":"Human monkeypox virus infection in women and non-binary individuals during the 2022 outbreaks: a global case series.","volume":"400","author":"Thornhill","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"jrv240029r35","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3201\/eid2905.230028","article-title":"Case report and literature review of occupational transmission of monkeypox virus to healthcare workers, South Korea.","volume":"29","author":"Choi","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"jrv240029r36","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S1473-3099(22)00806-4","article-title":"Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study.","volume":"23","author":"Fink","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"44","key":"jrv240029r37","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.15585\/mmwr.mm7144e1","article-title":"Severe monkeypox in hospitalized patients\u2014United States, August 10-October 10, 2022.","volume":"71","author":"Miller","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10380","key":"jrv240029r38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(23)00273-8","article-title":"Mpox in people with advanced HIV infection: a global case series.","volume":"401","author":"Mitj\u00e0","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"jrv240029r39","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1016\/j.ajt.2023.07.016","article-title":"Clinical features, treatment, and outcomes of mpox in solid organ transplant recipients: a multicenter case series and literature review.","volume":"23","author":"Higgins","year":"2023","journal-title":"Am J Transplant"},{"issue":"6","key":"jrv240029r40","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s11904-023-00682-w","article-title":"Mpox and HIV\u2014collision of two diseases.","volume":"20","author":"Zucker","year":"2023","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"6","key":"jrv240029r41","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ajog.2022.08.017","article-title":"Monkeypox in pregnancy: virology, clinical presentation, and obstetric management.","volume":"227","author":"Dashraath","year":"2022","journal-title":"Am J Obstet Gynecol"},{"key":"jrv240029r42","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2410045","article-title":"Mpox in pregnancy\u2014risks, vertical transmission, prevention, and treatment.","author":"Nachega","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv240029r43","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3390\/v16071123","article-title":"High rates of miscarriage and stillbirth among pregnant women with clade I mpox (monkeypox) are confirmed during 2023-2024 DR Congo outbreak in South Kivu Province.","volume":"16","author":"Schwartz","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"jrv240029r45","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28429","article-title":"Mpox diagnostics: review of current and emerging technologies.","volume":"95","author":"Lim","year":"2023","journal-title":"J Med Virol"},{"key":"jrv240029r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2024.105659","article-title":"Performance of the Xpert Mpox PCR assay with oropharyngeal, anorectal, and cutaneous lesion swab specimens.","volume":"171","author":"Damhorst","year":"2024","journal-title":"J Clin Virol"},{"issue":"10","key":"jrv240029r50","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29147","article-title":"How to distinguish mpox from its mimickers: an observational retrospective cohort study.","volume":"95","author":"Mortier","year":"2023","journal-title":"J Med Virol"},{"issue":"5","key":"jrv240029r51","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.jaad.2022.12.035","article-title":"A dermatologic assessment of 101 mpox (monkeypox) cases from 13 countries during the 2022 outbreak: skin lesion morphology, clinical course, and scarring.","volume":"88","author":"Prasad","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"jrv240029r53","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13678","article-title":"Scars are frequently found as late sequelae in individuals affected by the 2022 mpox outbreak.","author":"Chromy","journal-title":"HIV Med"},{"issue":"5","key":"jrv240029r54","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ICU.0000000000001066","article-title":"Ocular manifestations of mpox.","volume":"35","author":"Nguyen","year":"2024","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"jrv240029r55","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1097\/JU.0000000000003579","article-title":"Mpox genital lesions: a large single-center experience with intermediate follow-up.","volume":"210","author":"Lee","year":"2023","journal-title":"J Urol"},{"issue":"4","key":"jrv240029r56","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/QAD.0000000000003449","article-title":"Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort.","volume":"37","author":"Chastain","year":"2023","journal-title":"AIDS"},{"issue":"1","key":"jrv240029r57","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-252168","article-title":"Monkeypox-associated proctitis and rectal wall perforation.","volume":"16","author":"Brown","year":"2023","journal-title":"BMJ Case Rep"},{"issue":"4","key":"jrv240029r59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/infdis\/jiad034","article-title":"Clinical features, antiviral treatment, and patient outcomes: a systematic review and comparative analysis of the previous and the 2022 mpox outbreaks.","volume":"228","author":"Li","year":"2023","journal-title":"J Infect Dis"},{"issue":"8","key":"jrv240029r60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220415120","article-title":"Virulence differences of mpox (monkeypox) virus clades I, IIa, and IIb.1 in a small animal model.","volume":"120","author":"Americo","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"jrv240029r61","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1600-065X.2008.00691.x","article-title":"Monkeypox virus and insights into its immunomodulatory proteins.","volume":"225","author":"Weaver","year":"2008","journal-title":"Immunol Rev"},{"issue":"2","key":"jrv240029r63","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0002-9394(03)00293-9","article-title":"Ocular complications of smallpox vaccination.","volume":"136","author":"Pepose","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"jrv240029r64","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1001\/archopht.1976.03910040559015","article-title":"Treatment of Vaccinial keratitis with trifluorothymidine.","volume":"94","author":"Hyndiuk","year":"1976","journal-title":"Arch Ophthalmol"},{"issue":"10","key":"jrv240029r65","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2400189","article-title":"Tecovirimat use under expanded access to treat mpox in the United States, 2022-2023.","volume":"3","author":"Yu","year":"2024","journal-title":"NEJM Evid"},{"issue":"3","key":"jrv240029r66","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae029","article-title":"Association of tecovirimat therapy with mpox symptom improvement: a cross-sectional study\u2014King County, Washington, May-October 2022.","volume":"11","author":"Karmarkar","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"jrv240029r67","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28868","article-title":"Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.","volume":"95","author":"Mazzotta","year":"2023","journal-title":"J Med Virol"},{"issue":"6","key":"jrv240029r68","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jiac.2023.11.025","article-title":"Efficacy and viral dynamics of tecovirimat in patients with MPOX: a multicenter open-label, double-arm trial in Japan.","volume":"30","author":"Akiyama","year":"2024","journal-title":"J Infect Chemother"},{"issue":"3","key":"jrv240029r69","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamainternmed.2023.7696","article-title":"Early tecovirimat treatment for mpox disease among people with HIV.","volume":"184","author":"Aldred","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"12","key":"jrv240029r70","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.3201\/eid2912.231146","article-title":"Tecovirimat resistance in mpox patients, United States, 2022-2023.","volume":"29","author":"Smith","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"7","key":"jrv240029r71","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00568-23","article-title":"Identification of tecovirimat resistance-associated mutations in human monkeypox virus\u2014Los Angeles County.","volume":"67","author":"Garrigues","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"jrv240029r72","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00972-23","article-title":"Community spread of a human monkeypox virus variant with a tecovirimat resistance-associated mutation.","volume":"67","author":"Garrigues","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"jrv240029r73","doi-asserted-by":"publisher","first-page":"232","DOI":"10.15585\/mmwr.mm7209a4","article-title":"Interim clinical treatment considerations for severe manifestations of mpox\u2014United States, February 2023.","volume":"72","author":"Rao","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"jrv240029r74","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1001\/jamadermatol.2023.4727","article-title":"Successful treatment of recalcitrant mpox lesions with intralesional cidofovir in a patient with HIV\/AIDS.","volume":"160","author":"Buechler","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"8","key":"jrv240029r75","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: a retrospective observational study in the UK.","volume":"22","author":"Adler","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"jrv240029r76","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"jrv240029r77","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/cid\/ciac971","article-title":"The use of vaccinia immune globulin in the treatment of severe mpox virus infection in human immunodeficiency virus\/AIDS.","volume":"76","author":"Thet","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"35","key":"jrv240029r78","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.15585\/mmwr.mm7135e1","article-title":"Strategies adopted by gay, bisexual, and other men who have sex with men to prevent monkeypox virus transmission\u2014United States, August 2022.","volume":"71","author":"Delaney","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"22","key":"jrv240029r79","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm7122e1","article-title":"Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022.","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"jrv240029r82","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2022.18320","article-title":"Human monkeypox virus infection in the immediate period after receiving modified Vaccinia Ankara vaccine.","volume":"328","author":"Hazra","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"jrv240029r83","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1473-3099(23)00492-9","article-title":"Mpox in people with past infection or a complete vaccination course: a global case series.","volume":"24","author":"Hazra","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"jrv240029r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2023.104714","article-title":"Resurgence of symptomatic Mpox among vaccinated patients: first clues from a new-onset local cluster.","volume":"53","author":"Jamard","year":"2023","journal-title":"Infect Dis Now"},{"issue":"25","key":"jrv240029r85","doi-asserted-by":"publisher","first-page":"696","DOI":"10.15585\/mmwr.mm7225a6","article-title":"Notes from the field: emergence of an mpox cluster primarily affecting persons previously vaccinated against mpox\u2014Chicago, Illinois, March 18-June 12, 2023.","volume":"72","author":"Faherty","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"jrv240029r86","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/ije\/17.3.643","article-title":"The transmission potential of monkeypox virus in human populations.","volume":"17","author":"Fine","year":"1988","journal-title":"Int J Epidemiol"},{"issue":"37","key":"jrv240029r87","doi-asserted-by":"publisher","first-page":"16262","DOI":"10.1073\/pnas.1005769107","article-title":"Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo.","volume":"107","author":"Rimoin","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"jrv240029r88","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMc2300805","article-title":"Effectiveness of smallpox vaccination to prevent mpox in military personnel.","volume":"389","author":"Titanji","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv240029r89","doi-asserted-by":"publisher","first-page":"651","DOI":"10.3390\/vaccines12060651","article-title":"Effectiveness and safety of the MVA-BN vaccine against mpox in at-risk individuals in the United States (USMVAc).","volume":"12","author":"Back","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"jrv240029r90","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(23)00057-9","article-title":"Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.","volume":"23","author":"Bertran","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"jrv240029r91","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/cid\/ciad584","article-title":"Single-dose effectiveness of mpox vaccine in Quebec, Canada: test-negative design with and without adjustment for self-reported exposure risk.","volume":"78","author":"Brousseau","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"10","key":"jrv240029r92","doi-asserted-by":"publisher","DOI":"10.3201\/eid3010.240292","article-title":"Mpox epidemiology and vaccine effectiveness, England, 2023.","volume":"30","author":"Charles","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"20","key":"jrv240029r93","doi-asserted-by":"publisher","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","article-title":"Estimated effectiveness of JYNNEOS vaccine in preventing Mpox: a multijurisdictional case-control study\u2014United States, August 19, 2022-March 31, 2023.","volume":"72","author":"Dalton","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"26","key":"jrv240029r94","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1056\/NEJMoa2215201","article-title":"Vaccine effectiveness of JYNNEOS against mpox disease in the United States.","volume":"388","author":"Deputy","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv240029r95","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/cid\/ciad645","article-title":"Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic vaccination in a population at high risk of mpox: a Spanish cohort study.","volume":"78","author":"Font\u00e1n-Vela","year":"2024","journal-title":"Clin Infect Dis"},{"key":"jrv240029r96","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078243","article-title":"Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial.","volume":"386","author":"Navarro","year":"2024","journal-title":"BMJ"},{"issue":"11","key":"jrv240029r97","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad528","article-title":"Effectiveness of the Modified Vaccinia Ankara Vaccine against mpox in men who have sex with men: a retrospective cohort analysis, Seattle, Washington.","volume":"10","author":"Ramchandani","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"20","key":"jrv240029r98","doi-asserted-by":"publisher","first-page":"559","DOI":"10.15585\/mmwr.mm7220a4","article-title":"Effectiveness of JYNNEOS vaccine against diagnosed mpox infection\u2014New York, 2022.","volume":"72","author":"Rosenberg","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"jrv240029r99","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41591-023-02229-3","article-title":"Real-world effectiveness of a single dose of mpox vaccine in males.","volume":"29","author":"Wolff Sagy","year":"2023","journal-title":"Nat Med"},{"issue":"20","key":"jrv240029r100","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.035","article-title":"Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.","volume":"42","author":"Yeganeh","year":"2024","journal-title":"Vaccine"},{"issue":"6","key":"jrv240029r101","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.chom.2023.05.001","article-title":"Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals.","volume":"31","author":"Hubert","year":"2023","journal-title":"Cell Host Microbe"},{"issue":"3","key":"jrv240029r102","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.vaccine.2023.12.066","article-title":"JYNNEOS effectiveness as post-exposure prophylaxis against mpox: challenges using real-world outbreak data.","volume":"42","author":"Rosen","year":"2024","journal-title":"Vaccine"},{"issue":"50","key":"jrv240029r103","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200882","article-title":"Outcomes of post-exposure vaccination by modified Vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.","volume":"27","author":"Merad","year":"2022","journal-title":"Euro Surveill"},{"issue":"6","key":"jrv240029r105","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/S1473-3099(24)00287-1","article-title":"Shifting transmission patterns of human mpox in South Kivu, DR Congo.","volume":"24","author":"Katoto","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"jrv240029r106","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03130-3","article-title":"Sustained human outbreak of a new MPXV clade I lineage in eastern Democratic Republic of the Congo.","author":"Vakaniaki","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"jrv240029r107","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00062-23","article-title":"An APOBEC3 mutational signature in the genomes of human-infecting orthopoxviruses.","volume":"8","author":"Forni","year":"2023","journal-title":"mSphere"},{"issue":"6670","key":"jrv240029r108","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.adg8116","article-title":"APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016.","volume":"382","author":"O\u2019Toole","year":"2023","journal-title":"Science"},{"issue":"19","key":"jrv240029r109","doi-asserted-by":"publisher","first-page":"435","DOI":"10.15585\/mmwr.mm7319a3","article-title":"US preparedness and response to increasing clade I mpox cases in the Democratic Republic of the Congo\u2014United States, 2024.","volume":"73","author":"McQuiston","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"jrv240029r110","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2024.101465","article-title":"Mpox clade I outbreak and the first European case ex Africa, in Sweden\u2014a call for global health equity.","volume":"62","author":"Askling","year":"2024","journal-title":"New Microbes New Infect"},{"key":"jrv240029r52","author":"Cholli"},{"key":"jrv240029r2","unstructured":"Centers for Disease Control and Prevention. Mpox: ongoing 2022 global outbreak cases and data. Accessed May 1, 2024. https:\/\/archive.cdc.gov\/#\/details?q=https:\/\/www.cdc.gov\/poxvirus\/mpox\/response\/2022\/index.html"},{"key":"jrv240029r5","unstructured":"Centers for Disease Control and Prevention. National notifiable infectious diseases and conditions, United States: weekly tables. Accessed September 14, 2024. https:\/\/wonder.cdc.gov\/nndss\/nndss_weekly_tables_menu.asp"},{"key":"jrv240029r19","unstructured":"Centers for Disease Control and Prevention. Mpox infection prevention and control in healthcare settings. Accessed September 21, 2024. https:\/\/www.cdc.gov\/mpox\/hcp\/infection-control\/healthcare-settings.html"},{"key":"jrv240029r20","unstructured":"World Health Organization. Disease outbreak news: mpox\u2014African region. Accessed August 29, 2024. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2024-DON528"},{"key":"jrv240029r44","unstructured":"Centers for Disease Control and Prevention. Mpox laboratory information. September 27, 2024. https:\/\/www.cdc.gov\/mpox\/hcp\/laboratories\/index.html"},{"key":"jrv240029r46","unstructured":"US Food and Drug Administration. Xpert Mpox. Accessed September 19, 2024. https:\/\/www.fda.gov\/media\/165321\/download"},{"key":"jrv240029r48","unstructured":"US Food and Drug Administration. Labcorp Monkeypox PCR Test Home Collection Kit. Accessed September 19, 2024. https:\/\/www.fda.gov\/media\/177286\/download"},{"key":"jrv240029r49","unstructured":"Centers for Disease Control and Prevention. Mpox Vaccine Administration US map. Accessed September 21, 2024. https:\/\/archive.cdc.gov\/www_cdc_gov\/poxvirus\/mpox\/cases-data\/mpx-vaccine-admin-density.html"},{"key":"jrv240029r58","unstructured":"National Institutes of Health. The antiviral tecovirimat is safe but did not improve clade I mpox resolution in the Democratic Republic of the Congo. Accessed August 15, 2024. https:\/\/www.nih.gov\/news-events\/news-releases\/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo"},{"key":"jrv240029r62","unstructured":"Centers for Disease Control and Prevention. Clinical considerations for pain management. Accessed September 14, 2024. https:\/\/www.cdc.gov\/mpox\/hcp\/clinical-care\/pain-management.html"},{"key":"jrv240029r80","unstructured":"World Health Organization. WHO prequalifies the first vaccine against mpox. Published September 13, 2024. Accessed September 21, 2024. https:\/\/www.who.int\/news\/item\/13-09-2024-who-prequalifies-the-first-vaccine-against-mpox"},{"key":"jrv240029r81","unstructured":"Centers for Disease Control and Prevention. Interim clinical considerations for use of JYNNEOS vaccine for mpox prevention in the United States. Accessed May 1, 2024. https:\/\/www.cdc.gov\/poxvirus\/mpox\/clinicians\/vaccines\/vaccine-considerations.html"},{"key":"jrv240029r104","unstructured":"UNICEF. UNICEF scales up efforts to protect children as mpox outbreak spreads in the Democratic Republic of the Congo. Accessed September 14, 2024. https:\/\/www.unicef.org\/press-releases\/unicef-scales-efforts-protect-children-mpox-outbreak-democratic-republic-congo"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2825027\/jama_titanji_2024_rv_240029_1731080338.87945.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T11:07:16Z","timestamp":1732014436000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2825027"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":110,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,11,19]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.21091","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}